AstraZeneca (AZN LN) Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond."
2026 Guidance (reconfirmed)
- Total Revenue is expected to increase by a mid-to-high single-digit percentage
- Core EPS is expected to increase by a low double-digit percentage
Context
AstraZeneca's Q1 2026 results beat expectations on both revenue and adjusted EPS, indicating solid operational performance. The reaffirmation of guidance suggests confidence in their growth trajectory, which is favorable for investor sentiment, particularly in the pharmaceuticals sector. This could positively impact AstraZeneca's stock and potentially lift sector peers, given the strong outlook through 2030.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ASTRAZENECA PLC#AZN.LN#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#DXY#FTSE 100